{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:38:26Z","timestamp":1794335906241,"version":"4.9.0"},"reference-count":227,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Emergent BioSolutions"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2022,4,29]]},"DOI":"10.1080\/21645515.2021.1886560","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:38:02Z","timestamp":1621445882000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":26,"title":["Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases"],"prefix":"10.1080","volume":"18","author":[{"given":"Tharmala","family":"Tharmalingam","sequence":"first","affiliation":[{"name":"Therapeutics Business Unit, Emergent BioSolutions Incorporated, Winnipeg, MB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Han","sequence":"additional","affiliation":[{"name":"Therapeutics Business Unit, Emergent BioSolutions Incorporated, Winnipeg, MB, Canada"},{"name":"Department of Immunology, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Wozniak","sequence":"additional","affiliation":[{"name":"Therapeutics Business Unit, Emergent BioSolutions Incorporated, Winnipeg, MB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Saward","sequence":"additional","affiliation":[{"name":"Therapeutics Business Unit, Emergent BioSolutions Incorporated, Winnipeg, MB, Canada"},{"name":"Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"issue":"8","key":"cit0001","first-page":"1","volume":"57","author":"Baxter D.","year":"2007","journal-title":"Occup Med (Lond)"},{"issue":"20","key":"cit0002","volume":"7","author":"Pauna AM","year":"2019","journal-title":"SEA-Pract Appl Sci"},{"key":"cit0003","first-page":"54","volume":"1","author":"Verma P","year":"2010","journal-title":"Int J Pharm Stud Res"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1983.tb04126.x"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02139"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108459"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2020.1713756"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(91)90034-H"},{"key":"cit0009","volume-title":"Guidance for industry - safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency","author":"US Department of Health and Human Services","year":"2008"},{"issue":"2","key":"cit0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/biot.200500037","volume":"1","author":"Buchacher A","year":"2006","journal-title":"Biotechnol J: Healthcare Nutr Technol"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-08-100623-8.00043-8"},{"key":"cit0012","author":"Vandeberg P","year":"2020","journal-title":"bioRxiv"},{"key":"cit0013","volume-title":"KEDRAB (rabies immune globulin [human]). Full prescribing information","author":"Kamada Ltd","year":"2017"},{"key":"cit0014","volume-title":"CNJ-016 (Vaccinia immune globulin intravenous (Human) [VIGIV]). Full prescribing information","author":"Emergent BioSolutions Canada Inc","year":"2017"},{"key":"cit0015","volume-title":"CytoGam\u00ae (Cytomegalovirus immune globulin intravenous (Human)). Full prescribing information","author":"CSL Behring","year":"2018"},{"key":"cit0016","volume-title":"HepaGam B\u00ae (hepatitis B immune globulin intravenous [human]). Full prescribing information","author":"Saol Therapeutics Inc","year":"2018"},{"key":"cit0017","volume-title":"VARIZIG\u00ae ([Varicella zoster immune globulin (Human)]). Full prescribing information","author":"Saol Therapeutics Inc","year":"2018"},{"key":"cit0018","volume-title":"Nabi-HB\u00ae (hepatitis B immune globulin [human]). Full prescribing information","author":"ADMA Biologics","year":"2019"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-75-12-3493"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15797"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1067\/mem.2003.81"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw066"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701271"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2003.05.005"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.01.016"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2012.01.001"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2017.1328278"},{"key":"cit0029","unstructured":"U.S. Food and Drug Administration. Immune globulins. [accessed 2020 December 9]. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/immune-globulins."},{"key":"cit0030","unstructured":"Center for Biologic Evaluation and Research. List of licensed biological products with (1) reference product exclusivity and (2) biosimilarity or interchangeability evaluations to date. [accessed 2020 December 9]. https:\/\/www.fda.gov\/media\/89426\/download."},{"key":"cit0031","volume-title":"HyperRAB (Rabies immuno globulin (human). full prescribing information.). Full prescribing information","author":"Grifols Therapeutics Inc","year":"2019"},{"key":"cit0032","volume-title":"GamaSTAN\u00ae S\/D (immune globulin [human]). Full prescribing information","author":"Grifols Therapeutics Inc","year":"2013"},{"issue":"12","key":"cit0033","first-page":"212","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piz070"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217749"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-011-0795-6"},{"key":"cit0037","volume-title":"ANTHRASIL (anthrax immune globulin intravenous [human]). Full prescribing information","author":"Emergent BioSolutions","year":"2015"},{"key":"cit0038","volume-title":"HyperTET (Tetanus immune globulin (human). Full prescribing information.). Full Prescribing Information","author":"Grifols Therapeutics Inc","year":"2018"},{"key":"cit0039","volume-title":"BabyBIG (botulism immune globulin intravenous [human]). Full prescribing information","author":"Baxalta Inc","year":"2015"},{"key":"cit0040","volume-title":"BAT (botulism antitoxin heptavalent). Full prescribing information","author":"Emergent BioSolutions","year":"2017"},{"key":"cit0041","volume-title":"BioThrax (anthrax vaccine adsorbed). Full prescribing information","author":"Emergent BioSolutions","year":"2015"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(65)80436-X"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11090528"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2010.tb04073.x"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051926"},{"key":"cit0046","unstructured":"U.S. Food and Drug Administration. Code of federal regulations title 21 - subpart I: approval of new drug when human efficacy studies are not ethical or feasible. [accessed 2020 December 8]. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.9."},{"key":"cit0047","unstructured":"U.S. Food and Drug Administration. Code of federal regulations title 21 - subpart H: approval of biological products when human efficacy studies are not ethical or feasible. [accessed 2020 December 8]. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfCFR\/CFRSearch.cfm?CFRPart=601&showFR=1&subpartNode=21:7.0.1.1.2.8."},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-03053-7_14"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix816"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz515"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.3201\/eid2002.130687"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.3201\/eid2301.160608"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2013.10.025"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007059"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.16.2030"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2020.08.002"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2017.04.034"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/10-136"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2017.1371310"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2017.08.024"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808455"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-010-0094-6"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)92335-3"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.18.9894-9905.2003"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82459-0"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2875"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2011.05.002"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc070359"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-7-43"},{"key":"cit0070","first-page":"489","volume":"12","author":"Kong LK","year":"2006","journal-title":"Hong Kong Med J"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1200409109"},{"key":"cit0072","first-page":"151","volume":"11","author":"Makhoul B","year":"2009","journal-title":"Isr Med Assoc J"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.000079"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.3201\/eid2511.190537"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(84)90107-X"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.80.4.1972-1978.2006"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00179.x"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki346"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1271-9"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-017-0535-y"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1086\/600381"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01498"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3182706444"},{"key":"cit0084","first-page":"497","volume":"18","author":"Salehi H","year":"2013","journal-title":"J Res Med Sci"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.64.439"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2907"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2010.07.001"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq106"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq082"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1590\/S1984-82502013000400022"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30002-1"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3243"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1490-9"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.10.009"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1511812"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.11.009"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ334"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03910-7"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01548-18"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46291-9"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00234-y"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1088-9"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004168117"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1038\/nature06536"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.1016\/j.glt.2020.09.003"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009872"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.05.015"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111733"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4940"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-63794-y"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.09.023"},{"key":"cit0113","unstructured":"US Food and Drug Administration. CFR - Code of federal regulations title 21. [accessed 2020 December 8]. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=640&showFR=1&subpartNode=21:7.0.1.1.7.10"},{"key":"cit0114","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2016.12.014"},{"key":"cit0115","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00024-15"},{"key":"cit0116","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12312"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.18-0756"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008743"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2016.21.8.30148"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602113"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6539e1"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2016.42"},{"key":"cit0123","unstructured":"World Health Organization. Zika epidemiology update. [accessed 2020 December 8]. https:\/\/www.who.int\/emergencies\/diseases\/zika\/zika-epidemiology-update-july-2019.pdf"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314310"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1605367"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.1784"},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1604338"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602412"},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600651"},{"key":"cit0130","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.09.005"},{"key":"cit0131","doi-asserted-by":"publisher","DOI":"10.3390\/v11020092"},{"key":"cit0132","unstructured":"Kamada Ltd. Kamada provides update on progress related to its proprietary hyper-immunoglobulin (IgGs) platform technology including its commercial anti-rabies IgG and its pipeline products anti-corona (COVID-19) and Anti-Zika IgGs. [accessed 2020 December 8]. https:\/\/www.biospace.com\/article\/releases\/kamada-provides-update-on-progress-related-to-its-proprietary-hyper-immunoglobulin-iggs-platform-technology-including-its-commercial-anti-rabies-igg-and-its-pipeline-products-anti-corona-covid-19-and-anti-zika-iggs\/."},{"key":"cit0133","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw9066"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13589-1"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay2736"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.1700057"},{"key":"cit0137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310214"},{"issue":"2","key":"cit0138","first-page":"CD008545","volume":"2","author":"Eke AC","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0139","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21376"},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15674"},{"key":"cit0141","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.16.182105"},{"issue":"1","key":"cit0142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emi.2017.42","volume":"6","author":"Priyamvada L","year":"2019","journal-title":"Emerging Microbes Infect"},{"key":"cit0143","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6836"},{"key":"cit0144","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007060"},{"key":"cit0145","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006487"},{"key":"cit0146","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30496-5"},{"key":"cit0147","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.020421"},{"key":"cit0148","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0143-6"},{"key":"cit0149","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu269"},{"key":"cit0150","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp058291"},{"key":"cit0151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01677"},{"key":"cit0152","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030382"},{"key":"cit0153","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.030"},{"key":"cit0154","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40937-4"},{"key":"cit0155","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3684"},{"key":"cit0156","doi-asserted-by":"publisher","DOI":"10.1038\/srep37341"},{"issue":"6","key":"cit0157","volume":"93","author":"Arunkumar GA","year":"2019","journal-title":"J Virol"},{"key":"cit0158","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu396"},{"key":"cit0159","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy328"},{"key":"cit0160","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-11-70"},{"key":"cit0161","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0062"},{"key":"cit0162","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104753"},{"key":"cit0163","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.007823"},{"key":"cit0164","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv453"},{"key":"cit0165","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30253-X"},{"key":"cit0166","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30265-6"},{"key":"cit0167","unstructured":"World Health Organization. WHO coronavirus disease (COVID-19) dashboard. [accessed 2020 September 30]. https:\/\/covid19.who.int\/"},{"key":"cit0168","unstructured":"Plasma Protein Therapeutics Association. [accessed 2020 December 8]. https:\/\/www.pptaglobal.org\/"},{"key":"cit0169","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0311-8"},{"key":"cit0170","first-page":"e13477","author":"Fung M","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"cit0171","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.261784"},{"key":"cit0172","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-020-02384-2"},{"key":"cit0173","first-page":"204993612095793","volume":"7","author":"Khulood D","year":"2020","journal-title":"Ther Adv Infect Dis"},{"key":"cit0174","author":"Dogan M","year":"2020","journal-title":"medRxiv"},{"key":"cit0175","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3516"},{"key":"cit0176","unstructured":"U.S. Food and Drug Administration. EUA 26382: emergency use authorization (EUA) request. 2020."},{"issue":"2","key":"cit0177","first-page":"152","volume":"14","author":"Marano G","year":"2016","journal-title":"Blood Transfus"},{"key":"cit0178","author":"Steffen TL","year":"2020","journal-title":"bioRxiv"},{"key":"cit0179","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6952"},{"key":"cit0180","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.13.336800"},{"key":"cit0181","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd7728"},{"key":"cit0182","first-page":"ciaa721","author":"Wang X","year":"2020","journal-title":"Clin Infect Dis"},{"key":"cit0183","doi-asserted-by":"publisher","DOI":"10.1172\/JCI142004"},{"key":"cit0184","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000003"},{"key":"cit0185","author":"Wang R","year":"2020","journal-title":"Res Sq"},{"key":"cit0186","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00501"},{"key":"cit0187","author":"Van Egeren D","year":"2020","journal-title":"medRxiv"},{"key":"cit0188","author":"Lee CY-P","year":"2020","journal-title":"bioRxiv"},{"key":"cit0189","author":"Zhang L","year":"2020","journal-title":"bioRxiv"},{"key":"cit0190","author":"Klumpp-Thomas C","year":"2020","journal-title":"medRxiv"},{"key":"cit0191","author":"Thomson EC","year":"2020","journal-title":"bioRxiv"},{"key":"cit0192","unstructured":"Clinicaltrials.gov. Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients (SECR-01). [accessed 2020 December 8]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04610502."},{"key":"cit0193","unstructured":"Clinicaltrials.gov. Safety and efficacy of anti-SARS-CoV-2 equine antibody fragments (INOSARS) for hospitalized patients with COVID-19. [accessed 2020 December 8]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04514302."},{"key":"cit0194","unstructured":"Clinicaltrials.gov. Treatment with anti-SARS-CoV-2 immunoglobulin in patients with COVID-19. [accessed 2020 December 8]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04573855."},{"key":"cit0195","unstructured":"Clinicaltrials.gov. A study to investigate the pharmacokinetics, efficacy and safety of INM005 in patients with COVID-19. [accessed 2020 December 8]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04494984."},{"key":"cit0196","unstructured":"Clinicaltrials.gov. Safety, tolerability, and pharmacokinetics of SAB-185 in healthy participants. [accessed 2020 December 8]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04468958."},{"key":"cit0197","unstructured":"Clinicaltrials.gov. Safety, tolerability, and pharmacokinetics of SAB-185 in ambulatory participants with COVID-19. [accessed 2020 December 8]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04469179."},{"key":"cit0198","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2016.1171429"},{"key":"cit0199","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00226-17"},{"key":"cit0200","doi-asserted-by":"publisher","DOI":"10.1038\/srep24897"},{"key":"cit0201","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy430"},{"key":"cit0202","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf1061"},{"key":"cit0203","unstructured":"SAb Biotherapeutics. SAb biotherapeutics announces first participant dosed in phase 1 clinical trial of SAB-176 for seasonal influenza. [accessed 2020 November 18]. https:\/\/www.sabbiotherapeutics.com\/2020\/07\/30\/sab-biotherapeutics-announces-first-participant-dosed-in-phase-1-clinical-trial-of-sab-176-for-seasonal-influenza\/."},{"key":"cit0204","unstructured":"SAb Biotherapeutics. SAb biotherapeutics announces first participant dosed in phase 1 clinical trial of SAB-185 for the treatment and prevention of COVID-19. [accessed 2020 November 18]. https:\/\/www.sabbiotherapeutics.com\/2020\/08\/11\/sab-biotherapeutics-announces-first-participant-dosed-in-phase-1-clinical-trial-of-sab-185-for-the-treatment-and-prevention-of-covid-19\/."},{"key":"cit0205","author":"Vanhove B","year":"2020","journal-title":"bioRxiv"},{"key":"cit0206","unstructured":"Clinicaltrials.gov. First in human study: LIS1, an induction treatment in kidney transplanted patients. [accessed 2020 December 8]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04431219."},{"key":"cit0207","unstructured":"Clinicaltrials.gov. Study to evaluate the safety and efficacy of XAV-19 in patients with COVID-19 induced moderate pneumonia (POLYCOR). [accessed 2020 December 8]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04453384."},{"key":"cit0208","doi-asserted-by":"publisher","DOI":"10.1016\/j.coche.2013.08.005"},{"key":"cit0209","unstructured":"GigaGen I. GigaGen initiates large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050. [accessed 2020 November 18]. http:\/\/www.globenewswire.com\/news-release\/2020\/09\/09\/2091073\/0\/en\/GigaGen-Initiates-Large-Scale-Manufacturing-of-its-First-in-Class-Recombinant-Hyperimmune-Drug-for-COVID-19-GIGA-2050.html."},{"key":"cit0210","author":"Keating SM","year":"2020","journal-title":"bioRxiv"},{"key":"cit0211","unstructured":"GigaGen Inc. GigaGen receives NIH grant to develop production technology for recombinant intravenous immunoglobulin. [accessed 2020 November 18]. https:\/\/www.prnewswire.com\/news-releases\/gigagen-receives-nih-grant-to-develop-production-technology-for-recombinant-intravenous-immunoglobulin-300582135.html."},{"key":"cit0212","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2018.1503251"},{"key":"cit0213","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2015.999039"},{"key":"cit0214","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00290-15"},{"key":"cit0215","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0732-8"},{"key":"cit0216","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-1057-3"},{"key":"cit0217","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.12.004"},{"key":"cit0218","author":"Piepenbrink MS","year":"2020","journal-title":"bioRxiv"},{"key":"cit0219","author":"Rees V","year":"2020","journal-title":"Eur Pharm Rev"},{"key":"cit0220","unstructured":"Diomics Corp. A human antibody nasal spray under development might have prevented White House infections, scientists at Diomics and Active Motif say. [accessed 2021 January 19]. https:\/\/www.prnewswire.com\/news-releases\/a-human-antibody-nasal-spray-under-development-might-have-prevented-white-house-infections-scientists-at-diomics-and-active-motif-say-301148054.html."},{"key":"cit0221","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.11.057"},{"key":"cit0222","author":"Zhang H","year":"2020","journal-title":"bioRxiv"},{"key":"cit0223","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.09.242867"},{"key":"cit0224","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18174-5"},{"key":"cit0225","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01531"},{"key":"cit0226","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030486"},{"key":"cit0227","author":"Cohen J","year":"2020","journal-title":"Science"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2021.1886560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T13:09:21Z","timestamp":1657631361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2021.1886560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":227,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4,29]]}},"alternative-id":["10.1080\/21645515.2021.1886560"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2021.1886560","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1886560"}}